AVRO - AVROBIO, Inc.
| Previous Close | 20.02 |
| Open | 20.58 |
| Bid | 19.32 x 900 |
| Ask | 20.19 x 800 |
| Day's Range | 19.64 - 21.32 |
| 52 Week Range | 11.85 - 53.70 |
| Volume | 114,470 |
| Avg. Volume | 184,679 |
| Market Cap | 482.718M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.62 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.71 |
- Business Wire•26 days ago
AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
Recruitment completed in investigator-sponsored Phase 1 Fabry study
- Business Wire•2 months ago
AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will provide an overview of the Company and a business update. A live webcast of the presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at www.avrobio.com.
- Business Wire•2 months ago
AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced clinical trial updates from the ongoing investigator-sponsored Phase 1 clinical study and the AVROBIO-sponsored Phase 2 clinical trial of AVR-RD-01. AVR-RD-01 is an investigational gene therapy candidate designed to treat Fabry disease by inserting the GLA gene that encodes functional α-galactosidase A (AGA, the enzyme that is deficient in patients with Fabry disease) with the goal of enabling continuous endogenous AGA production and distribution to tissues and organs.
- Simply Wall St.•2 months ago
Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the February share price for AVROBIO, Read More...
- GlobeNewswire•3 months ago
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
CAMBRIDGE, Mass., Feb. 01, 2019 -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst.
- Zacks•3 months ago
AVROBIO Enters Oversold Territory
AVROBIO, Inc. (AVRO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- GlobeNewswire•3 months ago
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
The Phase 1/2 clinical trial is a planned investigator-sponsored trial to be conducted by the University of California, San Diego (UCSD) under the direction of Stephanie Cherqui, PhD, Associate Professor in the Department of Pediatrics at UCSD and a leading expert in stem cells and gene therapy for cystinosis.
- GlobeNewswire•3 months ago
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
CAMBRIDGE, Mass., Jan. 17, 2019 -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates.
- GlobeNewswire•3 months ago
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years’ experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The Company also announced that Scott Requadt is transitioning off AVROBIO’s board to become CEO of a Blackstone portfolio company. “Phil is a great addition to our Board,” said Geoff MacKay, President and CEO of AVROBIO.
- GlobeNewswire•4 months ago
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
AVROBIO, Inc. (AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.
- Insider Monkey•4 months ago
Should You Avoid AVROBIO, Inc. (AVRO)?
Is AVROBIO, Inc. (NASDAQ:AVRO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]
- GlobeNewswire•4 months ago
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease
AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-01, for the treatment of Fabry disease. The gene therapy consists of the patient’s own hematopoietic stem cells transduced with AVROBIO’s lentiviral vector, carrying a functional version of the GLA gene that encodes α‑galactosidase A (AGA) – the enzyme that is deficient in Fabry disease.
- GlobeNewswire•4 months ago
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 18, 2018 -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock.
- GlobeNewswire•4 months ago
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires
Three of them, Birgitte Volck, M.D., Ph.D., President of Research and Development, Erik Ostrowski, Chief Financial Officer, and Steven Avruch, General Counsel, will report to AVROBIO’s President and CEO, Geoff MacKay. The fourth, Josie Yang, Ph.D., Vice President and Head of Regulatory Affairs, will report to Dr. Volck.
- Benzinga•5 months ago
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
“The third quarter has been productive for AVROBIO,” commented Geoff MacKay, President and Chief Executive Officer of AVROBIO. “In a recent clinical data update on AVR-RD-01, we were pleased with the α‑galactosidase A (AGA) enzyme activity demonstrated in patients with Fabry disease. In addition, we have achieved our first regulatory milestone for our gene therapy for Gaucher disease as it advances towards the clinic.
- Benzinga•9 months ago
Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls
Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...
